Skip to content
Screener

Bio-Rad Laboratories BIO Q2 2026 earnings

Reported August 4, 2026 · After market close

Revenue$651.0MBeat by $27.0M
EPS$2.62Beat by $0.87
Revenue estimate$624.0M
EPS estimate$1.75
“Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating cash flow, and repurchased approximately $32 million of shares. We are reaffirming our full-year outlook, and remain focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation.”
Norman Schwartz

Next report

Nov 4, 2026 (In 2 days)
Revenue estimate$649.9M
EPS estimate$2.23

Financials

Q2 2026

Income statement

See full
Revenue$651.0M-0.1%
Gross profit$345.8M+0.1%
Operating income$72.6M-5.8%
Net income$371.4M+16.9%
EPS (diluted)$13.85+18.7%

Balance sheet

See full
Cash & equivalents$518.8M+39.6%
Total debt$979.1M-30.8%
Total equity$7.2B+0.6%
Total assets$10.3B+0.4%

Cash flow

See full
Operating cash flow$98.7M-15.3%
CapEx$32.0M-30.0%
Free cash flow$66.7M-5.8%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$10.28B+25.1%
Enterprise value$10.74B+16.4%
P/E46.2×+19.0×
P/S4×+0.8×

Profitability

See full
Gross margin51.9%-0.9pp
Net margin8.6%-3.9pp
FCF margin13.6%-0.9pp

Returns & leverage

See full
Return on equity3.1%-1.5pp
Debt / equity0.1×-0.1×
Current ratio3.1×-2.0×

Segments

By geography

See full
Europe$229.2M+5.5%
Asia Pacific$121.8M-3.6%
Americas$44.5M+8.3%

By segment

See full
Clinical Diagnostics$399.0M+2.6%
Life Science$252.0M-4.1%

FAQ

When did Bio-Rad Laboratories report Q2 2026 earnings?
Bio-Rad Laboratories (BIO) reported Q2 2026 earnings on August 4, 2026 after market close.
What were Bio-Rad Laboratories's Q2 2026 revenue and EPS?
Bio-Rad Laboratories reported revenue of $651.0M and eps of $2.62 for Q2 2026.
Did Bio-Rad Laboratories beat estimates in Q2 2026?
Revenue beat the consensus estimate of $624.0M by $27.0M. EPS beat the consensus estimate of $1.75 by $0.87.
How did Bio-Rad Laboratories's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.1% from $651.6M a year earlier and eps grew 0.4% from $2.61.
Where can I find Bio-Rad Laboratories's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000012208-26-000046) and the 10-Q periodic report (0000012208-26-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.